Literature DB >> 15619120

The metabotropic glutamate receptor 5 antagonist MPEP decreased break points for nicotine, cocaine and food in rats.

Neil E Paterson1, Athina Markou.   

Abstract

RATIONALE: The metabotropic glutamate (mGlu5) receptor subtype 5 antagonist MPEP attenuates self-administration of numerous drugs of abuse.
OBJECTIVES: The purpose of the present study was to explore whether MPEP-induced decreases in nicotine and cocaine self-administration reflect attenuation of the reinforcing and incentive motivational effects of nicotine and cocaine. The effects of MPEP on breaking points maintained by nicotine, cocaine or food were assessed using a progressive ratio schedule of reinforcement. Breaking points obtained under such schedules are postulated to reflect both the reinforcing and incentive motivational properties of reinforcers.
METHODS: Rats were allowed to respond for nicotine (0.05 mg/kg per infusion, free base), cocaine (0.18 mg/kg per infusion, salt), or food (45 mg pellets) under a progressive ratio schedule of reinforcement. After establishing stable and equivalent levels of responding for all three reinforcers, rats underwent one test session where no rewards were presented to assess the effects of 1-day extinction, similar to 1-day pharmacological-induced extinction, on performance in this schedule. Subsequently, rats were again allowed to respond for nicotine, cocaine or food until reestablishment of stable levels of responding. Then, MPEP (1-9 mg/kg) was administered intraperitoneally according to a within-subjects Latin square design, 30 min prior to the testing sessions.
RESULTS: Responding in the absence of a primary reinforcer was significantly decreased compared to responding under baseline conditions. Further, MPEP decreased break points maintained by nicotine, cocaine and food.
CONCLUSIONS: The mGlu5 receptor is implicated in mediating the reinforcing and incentive motivational properties of nicotine, cocaine and food.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15619120     DOI: 10.1007/s00213-004-2070-9

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  45 in total

1.  The GABA(B) agonist CGP 44532 decreases cocaine self-administration in rats: demonstration using a progressive ratio and a discrete trials procedure.

Authors:  K Brebner; W Froestl; M Andrews; R Phelan; D C Roberts
Journal:  Neuropharmacology       Date:  1999-11       Impact factor: 5.250

2.  Reinforcing and locomotor stimulant effects of cocaine are absent in mGluR5 null mutant mice.

Authors:  C Chiamulera; M P Epping-Jordan; A Zocchi; C Marcon; C Cottiny; S Tacconi; M Corsi; F Orzi; F Conquet
Journal:  Nat Neurosci       Date:  2001-09       Impact factor: 24.884

3.  Increased motivation for self-administered cocaine after escalated cocaine intake.

Authors:  Neil E Paterson; Athina Markou
Journal:  Neuroreport       Date:  2003-12-02       Impact factor: 1.837

4.  Repeated administration of the GABAB receptor agonist CGP44532 decreased nicotine self-administration, and acute administration decreased cue-induced reinstatement of nicotine-seeking in rats.

Authors:  Neil E Paterson; Wolfgang Froestl; Athina Markou
Journal:  Neuropsychopharmacology       Date:  2005-01       Impact factor: 7.853

5.  2-Methyl-6-(phenylethynyl)-pyridine (MPEP), a potent, selective and systemically active mGlu5 receptor antagonist.

Authors:  F Gasparini; K Lingenhöhl; N Stoehr; P J Flor; M Heinrich; I Vranesic; M Biollaz; H Allgeier; R Heckendorn; S Urwyler; M A Varney; E C Johnson; S D Hess; S P Rao; A I Sacaan; E M Santori; G Veliçelebi; R Kuhn
Journal:  Neuropharmacology       Date:  1999-10       Impact factor: 5.250

6.  Response-dependent versus response-independent presentation of cocaine: differences in the lethal effects of the drug.

Authors:  S I Dworkin; S Mirkis; J E Smith
Journal:  Psychopharmacology (Berl)       Date:  1995-02       Impact factor: 4.530

7.  Pretreatment with the dopamine agonist 7-OH-DPAT shifts the cocaine self-administration dose-effect function to the left under different schedules in the rat.

Authors:  S.B. Caine; G.F. Koob
Journal:  Behav Pharmacol       Date:  1995-06       Impact factor: 2.293

8.  The mGluR5 antagonist MPEP reduces the conditioned rewarding effects of cocaine but not other drugs of abuse.

Authors:  Andrew J McGeehan; M Foster Olive
Journal:  Synapse       Date:  2003-03       Impact factor: 2.562

9.  Effects of phentermine on responding maintained under multiple fixed-ratio schedules of food and cocaine presentation in the rhesus monkey.

Authors:  F H Wojnicki; R B Rothman; K C Rice; J R Glowa
Journal:  J Pharmacol Exp Ther       Date:  1999-02       Impact factor: 4.030

10.  Group II metabotropic and alpha-amino-3-hydroxy-5-methyl-4-isoxazole propionate (AMPA)/kainate glutamate receptors regulate the deficit in brain reward function associated with nicotine withdrawal in rats.

Authors:  Paul J Kenny; Fabrizio Gasparini; Athina Markou
Journal:  J Pharmacol Exp Ther       Date:  2003-06-12       Impact factor: 4.030

View more
  80 in total

1.  mGlu receptors and drug addiction.

Authors:  Richard M Cleva; M Foster Olive
Journal:  Wiley Interdiscip Rev Membr Transp Signal       Date:  2012-01-20

2.  Involvement of metabotropic glutamate receptor 5 in brain reward deficits associated with cocaine and nicotine withdrawal and somatic signs of nicotine withdrawal.

Authors:  Astrid K Stoker; Berend Olivier; Athina Markou
Journal:  Psychopharmacology (Berl)       Date:  2011-12-03       Impact factor: 4.530

3.  Activation of mGluR7s inhibits cocaine-induced reinstatement of drug-seeking behavior by a nucleus accumbens glutamate-mGluR2/3 mechanism in rats.

Authors:  Xia Li; Jie Li; Eliot L Gardner; Zheng-Xiong Xi
Journal:  J Neurochem       Date:  2010-06-08       Impact factor: 5.372

4.  Effects of metabotropic glutamate receptor 2/3 agonism and antagonism on schizophrenia-like cognitive deficits induced by phencyclidine in rats.

Authors:  Nurith Amitai; Athina Markou
Journal:  Eur J Pharmacol       Date:  2010-04-02       Impact factor: 4.432

Review 5.  Cognitive effects of Group I metabotropic glutamate receptor ligands in the context of drug addiction.

Authors:  M Foster Olive
Journal:  Eur J Pharmacol       Date:  2010-04-02       Impact factor: 4.432

6.  Discriminative stimulus effects of NMDA, AMPA, and mGluR5 glutamate receptor ligands in methamphetamine-trained rats.

Authors:  Thomas E Wooters; Linda P Dwoskin; Michael T Bardo
Journal:  Behav Pharmacol       Date:  2011-09       Impact factor: 2.293

7.  Partial mGlu₅ Negative Allosteric Modulators Attenuate Cocaine-Mediated Behaviors and Lack Psychotomimetic-Like Effects.

Authors:  Robert W Gould; Russell J Amato; Michael Bubser; Max E Joffe; Michael T Nedelcovych; Analisa D Thompson; Hilary H Nickols; Johannes P Yuh; Xiaoyan Zhan; Andrew S Felts; Alice L Rodriguez; Ryan D Morrison; Frank W Byers; Jerri M Rook; John S Daniels; Colleen M Niswender; P Jeffrey Conn; Kyle A Emmitte; Craig W Lindsley; Carrie K Jones
Journal:  Neuropsychopharmacology       Date:  2015-08-28       Impact factor: 7.853

8.  Interactive effects of the mGlu5 receptor antagonist MPEP and the mGlu2/3 receptor antagonist LY341495 on nicotine self-administration and reward deficits associated with nicotine withdrawal in rats.

Authors:  Matthias E Liechti; Athina Markou
Journal:  Eur J Pharmacol       Date:  2006-10-17       Impact factor: 4.432

Review 9.  Homers regulate drug-induced neuroplasticity: implications for addiction.

Authors:  Karen K Szumlinski; Alexis W Ary; Kevin D Lominac
Journal:  Biochem Pharmacol       Date:  2007-07-27       Impact factor: 5.858

10.  Marked global reduction in mGluR5 receptor binding in smokers and ex-smokers determined by [11C]ABP688 positron emission tomography.

Authors:  Funda Akkus; Simon M Ametamey; Valerie Treyer; Cyrill Burger; Anass Johayem; Daniel Umbricht; Baltazar Gomez Mancilla; Judit Sovago; Alfred Buck; Gregor Hasler
Journal:  Proc Natl Acad Sci U S A       Date:  2012-12-17       Impact factor: 11.205

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.